ImmunoGen, Inc(NASDAQ:IMGN) 
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ov...
Website: http://www.immunogen.com
Founded: 1981
Full Time Employees: 75
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2023-08-16
P
O 15.47
H 16.18
L 15.42
C 16.09
V 4,558,808
10EMA 16.09
20EMA 16.09
60EMA 16.09
120EMA 16.09
250EMA 16.09